Endothelin-1, aging and hypertension

Current Opinion in Cardiology

Volumn 23, Issue 4, 2008, Pages 350-355

  Stauffer, Brian L ^a,b   Westby, Christian M ^a   DeSouza, Christopher A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Aging; Endothelin 1; Endothelium; Hypertension

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; VERAPAMIL;

AEROBIC EXERCISE; AGING; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AGING; ANTIHYPERTENSIVE AGENTS; ASPARTIC ENDOPEPTIDASES; CALCIUM CHANNEL BLOCKERS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; METALLOENDOPEPTIDASES; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ENDOTHELIN;

EID: 44649116504     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328302f3c6     Document Type: Review

References (60)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
2. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 1991; 84:1457-1468.
3. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61:391-415.
4. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102:2434-2440.
5. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41:851-876.
6. Haynes WG, Strachan FE, Gray GA, Webb DJ. Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol 1995; 26 (Suppl 3):S40-S43.
7. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002; 160:297-304.
8. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 1999; 42:1383-1394.
9. Guarda E, Myers PR, Brilla CG, et al. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc Res 1993; 27:1004-1008.
10. Lavallee M, Takamura M, Parent R, Thorin E. Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 2001; 6:265-276.
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
12. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001; 14:83S-89S.
13. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29:736-743.
14. Van Guilder GP, Westby CM, Greiner JJ, et al. Endothelin-1 vasoconstrictor tone increases with age in healthy men but can be reduced by regular aerobic exercise. Hypertension 2007; 50:403-409. This is the first study to demonstrate an increase in endothelin system activity in otherwise healthy older adults. The data suggest that vasoconstrictor tone is enhanced with aging similarly to hypertension. Importantly, a program of moderate aerobic exercise is a viable therapy in reversing this age-related dysfunction.
15. Cardillo C, Campia U, Kilcoyne CM, et al. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002; 105:452-456.
16. Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33:753-758.
17. McEniery CM, Wilkinson IB, Jenkins DG, Webb DJ. Endogenous endothelin-1 limits exercise-induced vasodilation in hypertensive humans. Hypertension 2002; 40:202-206.
18. Nohria A, Garrett L, Johnson W, et al. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension 2003; 42:43-48.
19. Touyz RM, Schiffrin EL. Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003; 81:533-541.
20. Moreau P, d'Uscio LV, Shaw S, et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997; 96:1593-1597.
21. Best PJ, McKenna CJ, Hasdai D, et al. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 1999; 99:1747-1752.
22. Barton M, Haudenschild CC, d'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1998; 95:14367-14372.
23. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993; 27:1613-1618.
24. Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353-355.
25. Barone FC, White RF, Elliott JD, et al. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J Cardiovasc Pharmacol 1995; 26 (Suppl 3):S404-S407.
26. Tatlisumak T, Carano RA, Takano K, et al. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study. Stroke 1998; 29:850-857.
27. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001; 103:973-980.
28. Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 2001; 142:340-349.
29. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 2001; 37:1493-1505.
30. Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98:2235-2240.
31. Daull P, Blouin A, Belleville K, et al. Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats. Exp Biol Med (Maywood) 2006; 231:830-833.
32. Daull P, Benrezzak O, Arsenault D, et al. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 2005; 18:1606-1613.
33. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007; 50:247-256. A current review concerning the efficacy of a combined triple vasopeptidase inhibitor targeting the threemost important systems implicated in blood pressure control; renin-angotensin-aldosterone, natriuretic peptides and kinin, and endothelin.
34. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008; 153:1105-1119. A review examining the divergent success of current therapies targeting the endothelin system in cardiovascular diseases.
35. Battistini B, Berthiaume N, Kelland NF, et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) 2006; 231:653-695.
36. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N Engl J Med 1998; 338:784-790.
37. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15:583-589.
38. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007; 9:760-769. This randomized, double-blind, placebo-controlled study demonstrated the efficacy of the selective ETA receptor antagonist Darusentan in otherwise treatment-resistant hypertension.
39. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004; 109:1186-1193.
40. Calhoun DA, Renfoe K, Alper A. Oral sitaxsentan, an endothelin-a selective receptor antagonist, reduces systemic blood pressure in patients with mild-to-moderate primary hypertension [abstract]. Circulation 2000; 102:147.
41. Goddard J, Eckhart C, Johnston NR, et al. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004; 15:2601-2610.
42. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719.
43. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49:792-798. A well designed meta-analysis demonstrating the effectiveness of statin therapy on blood pressure reduction in hypercholesterolemic patients.
44. Siragy HM. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
45. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
46. King DE, Mainous AG III, Egan BM, et al. Use of statins and blood pressure. Am J Hypertens 2007; 20:937-941.
47. Kiowski W, Luscher TF, Linder L, Buhler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991; 83:469-475.
48. Sudano I, Virdis A, Taddei S, et al. Chronic treatment with long-acting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension. Hypertension 2007; 49:285-290. One of only two studies examining the effects of chronic calcium antagonism and endothelin system activity in hypertensive patients.
49. Feldstein C, Romero C. Role of endothelins in hypertension. Am J Ther 2007; 14:147-153. This current review examines the influence of endothelin-1 on organ systems known to be involved in mediating blood pressure.
50. Hong HJ, Chan P, Liu JC, et al. Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 2004; 61:159-168.
51. Medeo Modesti P, Zecchi-Orlandini S, Vanni S, et al. Release of preformed Ang II from myocytes mediates angiotensinogen and ET-1 gene overexpression in vivo via AT1 receptor. J Mol Cell Cardiol 2002; 34:1491-1500.
52. Moser L, Faulhaber J, Wiesner RJ, Ehmke H. Predominant activation of endothelin-dependent cardiac hypertrophy by norepinephrine in rat left ventricle. Am J Physiol Regul Integr Comp Physiol 2002; 282:R1389-R1394.
53. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987; 8:253-287.
54. Manson JE, Stampfer MJ, Hennekens CH, Willett WC. Body weight and longevity. A reassessment. JAMA 1987; 257:353-358.
55. Blair SN, Kohl HW III, Paffenbarger RS Jr, et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262:2395-2401.
56. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332:512-521.
57. Higashi Y, Sasaki S, Kurisu S, et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation 1999; 100:1194-1202.
58. Seals DR, Tanaka H, Clevenger CM, et al. Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. J Am Coll Cardiol 2001; 38:506-513.
59. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
60. American Heart Association. Heart and stroke facts: 2007 statistical supplement. Dallas, TX: American Heart Association; 2008.